Taken together, the critical CpG‐based signature facilitated clinicians to accurately predict the prognosis and evaluate the infiltration and anti‐tumour activity of CD8+ T cells in the TME of PC patients and choose more appropriate postoperative therapy individually. The gene discussed is CD8A; the disease is pachyonychia congenita.